Scarica l'app Stockscreener
539.88
1.27%
6.755
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Why Is Liquidia Stock Skyrocketing Wednesday?United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
A $10M payment is also due from United Therapeutics (UTHR) in its settlement with Liquidia. - Stock Titan
Liquidia shares surge to 5-month high premarket on United Therapeutics settlement - Yahoo Finance
Liquidia Shares Surge 42.48% After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360
Liquidia Just Paid $380 Million to End a Patent War That Crushed the Stock - Money Morning
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH - The Manila Times
Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits. - Stock Titan
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares - Investing.com
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 12 October - Investing.com Canada
The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Corporation Presents New Data Across Its Commercial and Development Portfolio At the CHEST 2026 Annual Meeting - marketscreener.com
An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting - Yahoo Finance
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com UK
United Therapeutics CEO Rothblatt sells $5.2m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 12 October By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.1m in shares - Investing.com
Form 4 United Therapeutics Corporation For: 10 October By Investing.com - Investing.com Nigeria
Is United Therapeutics Corp (UTHR) Overvalued After 3.1% Rally? - GuruFocus
After exercising 9,500 options, the CEO’s trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
McDermott team recognized by Law.com’s Litigation Daily for patent trial win for United Therapeutics - McDermott Will & Schulte
United Therapeutics chairperson & CEO Martine Rothblatt sells $5.2m in stock - Investing.com
The CEO's family trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Family trusts sell 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan
United Therapeutics Wipes Sandoz $70.6 Million Remodulin Win (1) - Bloomberg Law News
After exercising options at $117.76 per share, United Therapeutics (UTHR) CEO trust sells 9,500 shares. - Stock Titan
CEO trusts sold 9,500 United Therapeutics (UTHR) shares after exercising options at $117.76 each. - Stock Titan
After exercising 9,500 options, a CEO family trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics chairperson & CEO Rothblatt sells $1.06m - Investing.com
United Therapeutics EVP sells $4.69m in shares after option exercise - Investing.com
1.29%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):